Related Experiment Videos
Overview of phase I/II pemetrexed studies
Axel R Hanauske1, Christian Dittrich, Jorge Otero
1AK St. Georg, Department of Medicine, Hamburg, Germany. Hanauske.IND-Synergen@t-online.de
Oncology (Williston Park, N.Y.)
|January 20, 2005
Summary
Pemetrexed (Alimta) is an antifolate chemotherapy drug. Supplementation with folic acid and vitamin B12 significantly improved its tolerability in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Pemetrexed (Alimta) is an antifolate drug targeting key enzymes in cancer cell proliferation.
- Early trials evaluated pemetrexed as a single agent and in combination therapies.
Purpose of the Study:
- To review the clinical development and tolerability of pemetrexed.
- To assess pemetrexed's efficacy in combination chemotherapy regimens.
Main Methods:
- Phase I and II clinical trials were conducted to evaluate pemetrexed dosage and toxicity.
- Preclinical studies investigated pemetrexed's synergistic effects with other anticancer agents.
Main Results:
- Initial dose of 600 mg/m2 was adjusted to 500 mg/m2 due to toxicities.
- Pemetrexed demonstrated additive or synergistic activity with gemcitabine, fluorouracil, carboplatin, oxaliplatin, paclitaxel, and vinorelbine.
- Folic acid and vitamin B12 supplementation markedly enhanced pemetrexed tolerability.
Conclusions:
- Pemetrexed is well-tolerated as a single agent chemotherapy.
- Pemetrexed is a valuable component for combination chemotherapy regimens in cancer treatment.